AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

PhaseBio Pharmaceuticals to Present at the William Blair Biotech Focus Conference 2021 on July 15

June 30, 2021 GMT

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--Jun 30, 2021--

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that Chief Executive Officer Jonathan P. Mow will participate in a fireside chat during the upcoming William Blair Biotech Focus Conference 2021 taking place virtually on Thursday, July 15, 2021 at 1:00 pm – 1:45 pm EDT.

The event will be available via live webcast from the “Events and Presentations” page of the “Investors” section of the company’s website at www.phasebio.com. The webcast replay will be available for 90 days after the conclusion of the live presentation.

ADVERTISEMENT

About PhaseBio

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases. The company’s pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor; pemziviptadil (PB1046), a once-weekly VIP receptor agonist for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. PhaseBio’s proprietary elastin-like polypeptide technology platform enables the development of therapies with potential for less-frequent dosing and improved pharmacokinetics, including pemziviptadil, and drives both internal and partnership drug-development opportunities.

ADVERTISEMENT

PhaseBio is located in Malvern, PA, and San Diego, CA. For more information, please visit www.phasebio.com, and follow us on Twitter @PhaseBio and LinkedIn.

View source version on businesswire.com:https://www.businesswire.com/news/home/20210630005251/en/

CONTACT: PhaseBio Investor Contact:

John Sharp

Chief Financial Officer

(610) 981-6506

john.sharp@phasebio.comPhaseBio Media Contact:

Will Zasadny

Canale Communications, Inc.

(619) 961-8848

will.zasadny@canalecomm.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA PENNSYLVANIA

INDUSTRY KEYWORD: HEALTH OTHER HEALTH GENERAL HEALTH PHARMACEUTICAL CARDIOLOGY BIOTECHNOLOGY

SOURCE: PhaseBio Pharmaceuticals, Inc.

Copyright Business Wire 2021.

PUB: 06/30/2021 04:00 PM/DISC: 06/30/2021 04:02 PM

http://www.businesswire.com/news/home/20210630005251/en